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these. Retrospective reviews are still in progress, with all 
remaining data to be collected and analysed by the end of 
2014.  
A total of 84 objectives were not met in 63 plans (2.7% of all 
reviewed data), with 14 plans breaching more than one 
objective. The breakdown of all objectives not achieved as a 
percentage of the total number of cases with variations is 
presented below.  
 
 
On further examination 37 of the variations were in 
challenging cases, where clinical compromises were deemed 
necessary by the site principal investigator. In 8 plans a 
higher absolute dose maximum was accepted to a non-
clinically significant volume, as the V105% and V107% 
constraints were met. In 11 plans variations were due to 
misinterpretation of the DVH information at the investigator 
site and/or incorrect contouring of evaluation structures; in 
further 7 plans the reason was not clear. Therefore in 18 
plans (0.8% of all reviewed data) it may have been possible to 
improve the distribution to comply with protocol. 
The observed parameters varied across centres, which is 
attributed to different equipment, planning system and 
technique used. The differences in the median values for 
each dose objective across all centres is summarised below. 
 
 
Conclusions: The review performed on 2400 plans in the 
FAST-Forward trial demonstrates that the majority of plans 
comply with the dose objectives specified in the protocol, 
with only 2.7% of all reviewed data not achieving one or more 
of the dose objectives.  
The FAST-Forward trial is sponsored by the Institute of 
Cancer Research under the National Institute for Health 
Research – Health Technology Assessment programme 
(09/01/47) ISRCTN19906132 
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Purpose/Objective: The 'Utrecht cohort for Multiple BREast 
cancer intervention studies and Long-term evaLuAtion' 
(UMBRELLA) is a Dutch breast cancer cohort, aiming to gain 
insight into physical and emotional symptoms during and 
after breast cancer treatment and to evaluate (multiple) 
experimental interventions (e.g. novel radiotherapy 
treatments, physical activity interventions). In UMBRELLA the 
occurrence of breast edema is monitored, which can cause 
symptoms and decrease quality of life. The objective of this 
observational study is to evaluate prevalence, risk factors, 
edema-related toxicity and consequences of acute and 
chronic breast edema after surgery (i.e. lumpectomy, 
mastectomy, oncoplastic techniques, axillary lymph node 
dissection), irradiation (i.e. local, locoregional, regional) and 
(neo)adjuvant systemic therapy. 
Materials and Methods: As of October 2013, all women with 
breast cancer who are referred to our department of 
Radiation Oncology are invited to participate in UMBRELLA. 
Participants consent to clinical data collection and provide 
‘patient reported outcomes’ at regular time intervals during 
and after treatment. We estimated prevalence of breast 
edema according to CTCAE V4.0 scoring system as registered 
by radiation oncologists at weekly follow-up visits during 
irradiation, and at standard follow-up intervals after 
irradiation. We collected information on potential risk factors 
for edema, such as tumor size, patient characteristics (e.g. 
BMI) and treatment modalities. We performed univariate and 
multivariate logistic regression analysis to identify 
determinants that were (independently) associated with 
breast edema. Patient reported outcomes (i.e. quality of life, 
pain and cosmetic outcome) will be compared for patients 
with and without breast edema. The effect of different 
grades of edema on these patient reported outcomes will also 
be evaluated. 
Results: Between October 2013 and November 2014, 437 
breast cancer patients were enrolled in UMBRELLA. 
Preliminary results after analysis of the first 150 patients 
(median follow-up 49 days) showed that 23% of patients had 
acute breast edema within two months after the start of 
irradiation, of which 97% had ‘mild edema (grade 1)’. The 
proportion of breast edema was higher among patients who 
also received neo-adjuvant chemotherapy (44%), compared to 
21% in those who did not receive neo-adjuvant chemotherapy 
(p=0.024). No other determinants were significantly 
associated with breast edema.  
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Conclusions: Preliminary results showed acute breast edema 
in 1 out of 4 breast cancer patients undergoing irradiation 
after any surgical treatment and is more common after neo-
adjuvant chemotherapy. Updated results with a larger sample 
size and longer follow-up, as well as data on quality of life, 
pain and cosmetic results in association with acute and 
chronic breast edema will be presented at the ESTRO 
conference. 
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Purpose/Objective: First, to assess the long-term outcome of 
a retrospective cohort of 187 breast cancer (BC) patients who 
received pre-mastectomy radiotherapy. Second, to analyze 
predictive factors for disease-free survival (DFS) and overall 
survival (OS). 
Materials and Methods: From 1970 to 1984, 187 consecutive 
BC patients were treated with pre-mastectomy 
hypofractionated radiotherapy on whole breast, 
supraclavicular fossa, axilla +/- ipsilateral internal mammary 
lymph nodes (45-55Gy/18 fractions/34 days, IQR [31-36]). 
None received neo-adjuvant systemic treatment. Histology 
was centrally reviewed for the purpose of the present study. 
Local recurrence (LR), DFS and OS were estimated using the 
Kaplan-Meier method, survival comparisons by log-rank test, 
and prognostic factors by multivariable Cox models stratified 
on age. 
Results: Most patients (88%) had an early stage BC, 
characterized at that time by rapid growth (clinical doubling 
time < 6 months), and 122 (65%) were clinically N+. BCs were 
mainly T2 (91%) with some T3 (1%) and T4 (8%) tumours. 
Among the 166 reanalyzed biopsies 22% were triple negative, 
17% HER2 positive and 31% grade III. The median age was 49 
years [43-60]. ypT0, defined as the absence of residual 
invasive disease in the mastectomy specimen, was achieved 
in 26 patients (14%) and in 29% of triple negative patients. 
Pathological complete response defined as ypT0 + ypN0 was 
achieved in 18 patients (10%). The rate of ypT0 was linked to 
ypN0 status (OR=3.5, IC95% [1.2-10], p=0.02) and borderline 
to triple negative tumor status (OR=2.4, [0.9-6.7], p=0.08). 
The postoperative complication rate was 20% (37/187) with 
4.3% of skin necrosis (8/187). Adjuvant chemotherapy was 
delivered to 31% of patients. 
With a median follow-up of 32 years [23-35], the 10- and 25-
year rates were 9% [5% -15%] and 11% [7%-18%] for LR, 47% 
[40%-54%] and 30% [24%-37%] for DFS, 55% [47%-62%] and 30% 
[23%-37%] for OS. ypT0 was neither significantly related to 
LR, nor to DFS or OS. Triple negative patients experienced 
significantly more LR (HR=4.9 [1.2-21], adjusted on pN 
status). In the multivariable analysis on OS, pN status (HR= 
1.69, [1.28-2.22], p=0.0002), triple negative status (HR=1.80, 
[1.00-3.26], p=0.05) and HER2 status after 50 years (HR=3.46, 
[1.80-6.66], p=0.0002; test of interaction before 50 vs. after 
50, p=0.01) had significant prognostic impact. 
Conclusions: Long-term local control achieved by 
preoperative hypofractionated radiotherapy followed by 
radical mastectomy was excellent, with an acceptable rate of 
postoperative complications. These results might help 
identify subpopulations able to benefit from preoperative 
radiation therapy.  
   
PD-0433   
Acute and late complications of radiotherapy in women 
with implant-based breast reconstruction 
S. Braun1, K. Henne1, U. Nestle1, A. Grosu1, E. Stickeler2, J. 
Scholber1 
1Medical Center - University of Freiburg, Radiation Oncology, 
Freiburg, Germany  
2Medical Center - University of Freiburg, Gynecology, 
Freiburg, Germany  
 
Purpose/Objective: Radiotherapy of breast cancer patients 
with a tissue expander / implant (E/I) is a challenging 
intervention due to possible complications. Capsular fibrosis 
is one the most important side effects. It may lead to 
removal or exchange of the E/I (reconstruction failure). 
Other complications such as breast / chest wall pain and 
lymph edema can also considerably decrease the quality of 
life (QoL) of these women. The main purpose of this analysis 
was to assess the incidence and severity of acute and late 
local toxicity as well as the rate of reconstruction failure. An 
additional aim was to examine QoL and patient satisfaction 
with the breast reconstruction. 
Materials and Methods: We identified 58 women (age 33 – 74 
at the time of radiotherapy) with E/I who were treated with 
radiotherapy due to breast cancer at our institution between 
February 2000 and December 2013. Among them, 52 had a 
mastectomy with primary breast reconstruction and 6 already 
had breast implants for cosmetic reasons before first 
diagnosis of breast cancer. The total radiotherapy dose was 
between 50 and 60.4 Gy (single dose 1.8 or 2 Gy). Acute and 
late side effects were scored according to CTCAE v.4.03. To 
investigate QoL and satisfaction with the breast 
reconstruction the EORTC questionnaires QLQ-C30 / QLQ-
BR23 as well as three additional questions were used. Median 
follow up was 2.3 years. 
Results: The most common acute side effects were radiation 
dermatitis (91.4 %), skin hyperpigmentation (46.6 %), breast / 
chest wall pain (24.2 %) and lymph edema (13.7 % in the 
breast/chest wall, 6.8% in the arm). As late complications, 
we observed most frequently skin hyperpigmentation (34.5 
%), breast / chest wall pain (22.4 %) and lymph edema (6.8 % 
in the breast / chest wall, 18.9 % in the arm). Severe 
capsular fibrosis (Baker grade III and IV) occurred in 25.1 % of 
the women. Reconstruction failure was detected in 25.9 % 
and only during the first 4.6 years after radiotherapy. 
Compared to EORTC reference values for breast cancer 
patients, our patients showed similar outcome for QoL. Most 
women were well (55.0 %) or moderately (35.0 %) satisfied 
with their breast reconstruction and 75.0 % would choose the 
same way of breast reconstruction again. 
Conclusions: There are no established risk factors for 
complications in patients with E/I after radiation therapy. 
Thus, women suffering from breast cancer have to be well 
educated about potential risks by primary implant-based 
breast reconstruction and adjuvant radiotherapy. It is very 
important that a multidisciplinary team together with the 
patient finds the best individual approach for cancer 
treatment and breast reconstruction when mastectomy and 
radiotherapy might be necessary.  
